Pregabalin Open-Label Extension Trial in Patients With Partial Seizures
NCT ID: NCT00143143
Last Updated: 2006-07-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
300 participants
INTERVENTIONAL
2001-09-30
2006-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pregabalin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Be currently taking 1 to 3 AEDs.
Exclusion Criteria
* Experienced a serious adverse event during Study 1008-157 which was determined to be possibly related to study medication
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Bonn, , Germany
Pfizer Investigational Site
Essen, , Germany
Pfizer Investigational Site
Frankfurt, , Germany
Pfizer Investigational Site
Freiburg im Breisgau, , Germany
Pfizer Investigational Site
Göttingen, , Germany
Pfizer Investigational Site
Kehl, , Germany
Pfizer Investigational Site
Innsbruck, , Austria
Pfizer Investigational Site
Mauer bei Amstetten, , Austria
Pfizer Investigational Site
Sankt Pölten, , Austria
Pfizer Investigational Site
Vienna, , Austria
Pfizer Investigational Site
Calgary, Alberta, Canada
Pfizer Investigational Site
Edmonton, Alberta, Canada
Pfizer Investigational Site
Vancouver, British Columbia, Canada
Pfizer Investigational Site
Halifax, Nova Scotia, Canada
Pfizer Investigational Site
Barrie, Ontario, Canada
Pfizer Investigational Site
London, Ontario, Canada
Pfizer Investigational Site
Ottawa, Ontario, Canada
Pfizer Investigational Site
Trois-Rivières, Quebec, Canada
Pfizer Investigational Site
Marseille, Cedex 05, France
Pfizer Investigational Site
Paris, Cedex 13, France
Pfizer Investigational Site
Montpellier, Cedex 5, France
Pfizer Investigational Site
Lille, Cedex, France
Pfizer Investigational Site
Rennes, Cedex, France
Pfizer Investigational Site
Colomiers, , France
Pfizer Investigational Site
Dommartin-lès-Toul, , France
Pfizer Investigational Site
Marseille, , France
Pfizer Investigational Site
Strasbourg, , France
Pfizer Investigational Site
Berlin, , Germany
Pfizer Investigational Site
Berlin, , Germany
Pfizer Investigational Site
Bielefeld, , Germany
Pfizer Investigational Site
Marburg, , Germany
Pfizer Investigational Site
Ulm, , Germany
Pfizer Investigational Site
Florence, , Italy
Pfizer Investigational Site
Perugia, , Italy
Pfizer Investigational Site
Pisa, , Italy
Pfizer Investigational Site
Siena, , Italy
Pfizer Investigational Site
Vilnius, , Lithuania
Pfizer Investigational Site
Vilnius, , Lithuania
Pfizer Investigational Site
Barcelona, Barcelona, Spain
Pfizer Investigational Site
Girona, Gerona, Spain
Pfizer Investigational Site
Madrid, Madrid, Spain
Pfizer Investigational Site
Madrid, Madrid, Spain
Pfizer Investigational Site
Donostia / San Sebastian, , Spain
Pfizer Investigational Site
Glascow, Scotland, United Kingdom
Pfizer Investigational Site
Fazakerley, Liverpool, , United Kingdom
Pfizer Investigational Site
York, , United Kingdom
Pfizer Investigational Site
, ,
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1008-000-164
Identifier Type: -
Identifier Source: org_study_id